KQ-2002

N/A

Report date: 2024/06/11 20:00:08

Base Information

Drug NameKQ-2002
Drug Alias NameKQ-2002
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy > Dual-target CAR-T cell therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-CD19Anti-CD22
TargetsB-lymphocyte antigen CD19CD22
Therapy Area/IndicationsMultiple MyelomaLymphoma, B-CellPrecursor Cell Lymphoblastic Leukemia-Lymphoma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesNovatim Immune Therapeutics (Zhejiang) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNovatim Immune Therapeutics (Zhejiang) Co Ltd
Inactive CompaniesN/A
Active IndicationsMultiple MyelomaLymphoma, B-CellPrecursor Cell Lymphoblastic Leukemia-Lymphoma +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A